Comment The use of CDK 46 inhibitors now translates to a significant survival benefit in breast cancer treatment

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment

13:41 EDT 1 Jun 2019 | ecancermedicalscience

Dr Harold Burstein comments on data, during a press conference at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, from the MONALEESA-7 trial. This was a phase III randomised trial in which patients with with pre-menopausal women...

More From BioPortfolio on "Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment"